1. Matjaz Barboric  Is a corresponding author
  2. Koh Fujinaga  Is a corresponding author
  1. University of Helsinki, Finland
  2. University of California, San Francisco, United States

Like all viruses, human immunodeficiency virus (HIV) must engage with the cells of its host to be able to replicate. Compared to other retroviruses, this interaction is particularly complex in the case of HIV because its genome encodes many proteins that take advantage of various cell processes and counteract host defenses. One of these proteins is called transactivator of transcription (Tat) and it is essential for the expression of HIV genes in host cells. Now, in eLife, Ivan D’Orso of the University of Texas Southwestern Medical Center (UTSW) and colleagues – including Jonathan Reeder and Youn-Tae Kwak of UTSW as joint first authors – demonstrate that Tat can also regulate the expression of many host genes (Reeder et al., 2015).

In the first stage of gene expression, a gene is “transcribed” to make messenger RNA (mRNA) by an enzyme called RNA polymerase II (Pol II). After Pol II binds to the promoter region of a gene and starts to make an mRNA molecule, the enzyme stops due to the actions of pause-inducing factors. The ability of Pol II to continue to transcribe the gene (in a step called elongation) depends on a cellular protein complex called P-TEFb (short for positive transcription elongation factor b). In the case of HIV, the situation is very similar. Pol II pauses soon after initiating from the promoter of the viral genome producing only short mRNAs. However, Tat can override this transcriptional block by recruiting P-TEFb to Pol II via a RNA stem-loop structure called the transactivation response element, which is found at the beginning of all virus mRNAs (Ott et al., 2011).

While most researchers have focused on understanding how Tat activates the transcription of HIV, some studies have demonstrated that Tat also alters the expression of host genes to promote the production and spread of HIV. For example, Tat manipulates immune T cells in its host to allow the virus to infect and replicate in them (Li et al., 1997, Huang et al., 1998). Moreover, Tat induces the expression of chemokines that attract uninfected T cells and macrophages, facilitating expansion of HIV in the host (Izmailova et al., 2003). On the other side, Tat can also contribute to the depletion of T cells during AIDS progression by up-regulating cellular pro-apoptotic genes (Kim et al., 2010). Finally, Tat is able to repress the transcription of several genes encoding receptors of the innate immune system responses. However, we still do not have a comprehensive view of the host genes that Tat targets, or how Tat alters the transcription of these genes.

Reeder, Kwak, D'Orso and two colleagues – Ryan McNamara (UTSW) and Christian Forst (Icahn School of Medicine at Mount Sinai) – took on this challenge by analyzing T cells that produced the Tat protein with a series of genome-wide approaches. They identified close to 3000 sites in the human genome that are occupied by Tat. The presence of Tat changed the expression of about 2000 host genes, and almost quarter of these were classified as direct targets because Tat bound to their promoters or to other sites in the genes. About half of these direct targets were up-regulated by Tat, while the rest were down-regulated. Further experiments revealed that for a subset of the target genes, Tat is able to regulate either the initiation or elongation by Pol II.

Next, Reeder, Kwak et al. investigated how Tat can modulate different steps in the transcription of host genes. For example, to stimulate or inhibit the start of transcription, Tat regulates the loading Pol II to cellular promoters. Of note, at the majority of up-regulated genes, Tat appears to facilitate Pol II promoter presence from sites within gene bodies by inducing DNA looping. However, to regulate elongation, Tat can either promote or prevent the recruitment of P-TEFb to specific genes. Importantly, Reeder, Kwak et al.’s further findings suggest that, unlike what happens with viral genes, Tat does not seem to rely on RNA structures similar to the HIV transactivation response element to regulate target host genes. Instead, Tat co-opts some of the master transcriptional regulators of its host that also control cellular gene transcription in uninfected cells.

In agreement with an earlier report (Marban et al., 2011), Reeder, Kwak et al. found that binding sites for the master regulator called ETS1 were, among others, most frequent near the genomic regions that Tat occupies. Tat interacts with ETS1 protein and knocking down the ETS1 gene abolished the recruitment of Tat to some target genes, thus preventing it from being able to modulate their transcription. Moreover, ETS1 motifs are found at both up-regulated and down-regulated Tat targets, underscoring that gene-specific circumstances determine the effect of Tat. Curiously, HIV itself contains an ETS1 binding site upstream of its promoter, and this allows ETS1 to stimulate viral gene expression in collaboration with other transcription factors of the cell (Sieweke et al., 1998; Yang et al., 2009).

The report by Reeder, Kwak et al. arguably represents the most thorough characterization of the role of Tat on host gene expression. While making sure that the HIV genome is transcribed, Tat also fine-tunes two critical steps in the expression of specific cellular genes. Is this tweaking of host gene transcription a necessary survival strategy for HIV, or merely a side effect of the presence of potent transcriptional regulator Tat in the cell nucleus? Or has this possible side effect been transformed through evolution into a winning strategy of the virus? Whatever the correct answer might be, Reeder, Kwak et al. confirmed that the expression of many Tat target genes changed as expected during HIV infection. Moreover, many of these genes appear to be involved in signaling pathways and biological processes that could help HIV to spread in the host.

This study raises further questions. Does Tat modulate the expression of hundreds of previously identified host proteins that interact with HIV gene products or are critical to replication of the virus? Is Tat also capable of regulating the termination of transcription at host genes? How exactly do the interactions between Tat, master transcriptional regulators like ETS1, and host proteins lead to changes in gene expression? Further, has HIV devised one strategy to promote very high levels of transcription of its own genome, while exploiting cellular transcriptional regulators to provoke only modest (but beneficial) changes in the expression of host genes? Answers to these and other questions shall advance our understanding of how and why HIV Tat reprograms its host.

References

    1. Huang L
    2. Bosch I
    3. Hofmann W
    4. Sodroski J
    5. Pardee AB
    (1998)
    Tat protein induces human immunodeficiency virus type 1 (hIV-1) coreceptors and promotes infection with both macrophage-tropic and t-lymphotropic HIV-1 strains
    Journal of Virology 72:8952–8960.

Article and author information

Author details

  1. Matjaz Barboric

    Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland
    For correspondence
    matjaz.barboric@helsinki.fi
    Competing interests
    The authors declare that no competing interests exist.
  2. Koh Fujinaga

    Department of Medicine, University of California, San Francisco, San Francisco, United States
    For correspondence
    koh.fujinaga@ucsf.edu
    Competing interests
    The authors declare that no competing interests exist.

Publication history

  1. Version of Record published: January 19, 2016 (version 1)

Copyright

© 2016, Barboric et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,972
    views
  • 239
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matjaz Barboric
  2. Koh Fujinaga
(2016)
HIV: The two sides of Tat
eLife 5:e12686.
https://doi.org/10.7554/eLife.12686

Further reading

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Gregory Caleb Howard, Jing Wang ... William P Tansey
    Research Article

    The chromatin-associated protein WD Repeat Domain 5 (WDR5) is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the ‘WIN’ site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the most notable of which are those derived from MLL-rearranged (MLLr) leukemias. Peptidomimetic WINi were originally proposed to inhibit MLLr cells via dysregulation of genes connected to hematopoietic stem cell expansion. Our discovery and interrogation of small-molecule WINi, however, revealed that they act in MLLr cell lines to suppress ribosome protein gene (RPG) transcription, induce nucleolar stress, and activate p53. Because there is no precedent for an anticancer strategy that specifically targets RPG expression, we took an integrated multi-omics approach to further interrogate the mechanism of action of WINi in human MLLr cancer cells. We show that WINi induce depletion of the stock of ribosomes, accompanied by a broad yet modest translational choke and changes in alternative mRNA splicing that inactivate the p53 antagonist MDM4. We also show that WINi are synergistic with agents including venetoclax and BET-bromodomain inhibitors. Together, these studies reinforce the concept that WINi are a novel type of ribosome-directed anticancer therapy and provide a resource to support their clinical implementation in MLLr leukemias and other malignancies.

    1. Chromosomes and Gene Expression
    2. Immunology and Inflammation
    Rajan M Thomas, Matthew C Pahl ... Andrew D Wells
    Research Article

    Ikaros is a transcriptional factor required for conventional T cell development, differentiation, and anergy. While the related factors Helios and Eos have defined roles in regulatory T cells (Treg), a role for Ikaros has not been established. To determine the function of Ikaros in the Treg lineage, we generated mice with Treg-specific deletion of the Ikaros gene (Ikzf1). We find that Ikaros cooperates with Foxp3 to establish a major portion of the Treg epigenome and transcriptome. Ikaros-deficient Treg exhibit Th1-like gene expression with abnormal production of IL-2, IFNg, TNFa, and factors involved in Wnt and Notch signaling. While Ikzf1-Treg-cko mice do not develop spontaneous autoimmunity, Ikaros-deficient Treg are unable to control conventional T cell-mediated immune pathology in response to TCR and inflammatory stimuli in models of IBD and organ transplantation. These studies establish Ikaros as a core factor required in Treg for tolerance and the control of inflammatory immune responses.